



5  
1/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Paul et al.

Confirmation No.: 9112

Serial No.: 09/828,625

Art Unit: 3738

Filed: April 9, 2001

Examiner: Suzette J. Gherbi

For: INTERVERTEBRAL  
ALLOGRAFT SPACER

Attorney Docket No: 8932-295

**STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. § 1.133**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. § 1.133 and M.P.E.P. § 713.04, Applicants submit this Statement of Substance of Interview for the personal interview of May 5, 2005 between Examiner Suzette J. Gherbi, and Applicants' representative Brent P. Ray in connection with the above-identified application.

During the Interview, amendments to claims 24, 28, 41, 53, 57, 66, and 67 were discussed, and agreed upon. These amendments were made to better conform the claims to the specification. No admissions were made by Applicants regarding 35 U.S.C. § 112 issues, and therefore these amendments should not create any estoppel effect.

No fee is believed to be due for this Statement. Should any fee be due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: July 1, 2005

  
54,390

(Reg. No.)

Brent P. Ray  
JONES DAY  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Paul et al.

Confirmation No.: 9112

Serial No.: 09/828,625

Art Unit: 3738

Filed: April 9, 2001

Examiner: Suzette J. Gherbi

For: INTERVERTEBRAL  
ALLOGRAFT SPACER

Attorney Docket No: 8932-295

**AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. § 1.312**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Supplemental Notice of Allowability dated May 25, 2005, and pursuant to the telephone conversation between the undersigned and Examiner Gherbi on May 5, 2005, Applicants respectfully request that the above-identified application be amended pursuant to 37 C.F.R. § 1.312.

**Amendments to the Claims begin on page 2 of this Response**

**Remarks begin on page 11 of this Response**

**Conclusion begins on page 11 of this Response**